SMARCA4 and lung carcinoma: Furthermore, immunohistochemistry (IHC) analyses have demonstrated a loss of BRM and BRG1 in 15-35% and 20-50% of human tumors, respectively, with concomitant down-regulation of these subunits in 30% of lung cancer cell lines and 10% of primary lung tumors [9, 11].